Measurement of carcinoembryonic antigen in patients with bronchogenic carcinoma

Estimation of CEA levels by the Z‐gel method indicates that smokers, patients with limited lung cancer and patients with extensive lung cancer have higher values than nonsmoking controls. The CEA levels within each group are significantly different from one another. Use of CEA estimation for diagnos...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer 1978-09, Vol.42 (S3), p.1484-1491
Hauptverfasser: Dent, Peter B., McCulloch, Peter B., Wesley‐James, Oliver, Maclaren, Robert, Muirhead, William, Dunnett, Charles W.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1491
container_issue S3
container_start_page 1484
container_title Cancer
container_volume 42
creator Dent, Peter B.
McCulloch, Peter B.
Wesley‐James, Oliver
Maclaren, Robert
Muirhead, William
Dunnett, Charles W.
description Estimation of CEA levels by the Z‐gel method indicates that smokers, patients with limited lung cancer and patients with extensive lung cancer have higher values than nonsmoking controls. The CEA levels within each group are significantly different from one another. Use of CEA estimation for diagnostic purposes is limited because of the considerable overlap between normal controls and patients with cancer, the relatively low incidence of elevated values in patients with limited disease and the high incidence of false negatives (20%) even in patients with extensive disease. Elevated CEA values are associated with a poor prognosis and could be of clinical value as an addition to clinical staging to determine survival particularly for patients with extrathoracic disease. Persistently high values in patients deemed clinically disease‐free postoperatively are indicative of residual disease and a poor prognosis. If and when effective therapy for bronchogenic carcinoma becomes available, monitoring of CEA values may be useful in some patients as an early indication of relapse. Further studies are required to determine if the extraordinarily poor prognosis associated with marked elevations of CEA may be used as an additional criterion of inoperability in such patients.
doi_str_mv 10.1002/1097-0142(197809)42:3+<1484::AID-CNCR2820420819>3.0.CO;2-J
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_74215308</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>74215308</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4639-34dac14bdb9b45a59b9afabba9bb8cdd9be0d2ab52e01d2226942fab909160e33</originalsourceid><addsrcrecordid>eNqNkF9LHDEUxYOodWv9Bn2Yp6LIbG_-zM5kK4JO1SrWBVEQXy5JJltTdmbWZBbZb2_WWYT2ofTp5nLOPSf8CDmlMKQA7CsFmadABdunMi9AHgg25odHVBRiPD65_J6WN-UtKxgIBgWVx3wIw3LyjaVXG2TwfrxJBgBQpJngDzvkYwi_45qzjH8g2znIjMoBmfy0Kiy8rW3TJe00Mcob17S21n7ZNs4kquncL9skrknmqnPRFpIX1z0l2reNeWqjFl3rs1p9IltTNQt2bz13yf352V35I72eXFyWJ9epESMuUy4qZajQlZZaZCqTWqqp0lpJrQtTVVJbqJjSGbNAK8bYSAoWDRIkHYHlfJd86XPnvn1e2NBh7YKxs5lqbLsImAtGMw5FND72RuPbELyd4ty7WvklUsAVbFzxwhUv7GFjfHHEFWzECBv_hB01wHKCDK9i-Of1Lxa6ttV7dE83ylUvv7iZXf5n8VvvP2v_UvgrbDueDw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>74215308</pqid></control><display><type>article</type><title>Measurement of carcinoembryonic antigen in patients with bronchogenic carcinoma</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Dent, Peter B. ; McCulloch, Peter B. ; Wesley‐James, Oliver ; Maclaren, Robert ; Muirhead, William ; Dunnett, Charles W.</creator><creatorcontrib>Dent, Peter B. ; McCulloch, Peter B. ; Wesley‐James, Oliver ; Maclaren, Robert ; Muirhead, William ; Dunnett, Charles W.</creatorcontrib><description>Estimation of CEA levels by the Z‐gel method indicates that smokers, patients with limited lung cancer and patients with extensive lung cancer have higher values than nonsmoking controls. The CEA levels within each group are significantly different from one another. Use of CEA estimation for diagnostic purposes is limited because of the considerable overlap between normal controls and patients with cancer, the relatively low incidence of elevated values in patients with limited disease and the high incidence of false negatives (20%) even in patients with extensive disease. Elevated CEA values are associated with a poor prognosis and could be of clinical value as an addition to clinical staging to determine survival particularly for patients with extrathoracic disease. Persistently high values in patients deemed clinically disease‐free postoperatively are indicative of residual disease and a poor prognosis. If and when effective therapy for bronchogenic carcinoma becomes available, monitoring of CEA values may be useful in some patients as an early indication of relapse. Further studies are required to determine if the extraordinarily poor prognosis associated with marked elevations of CEA may be used as an additional criterion of inoperability in such patients.</description><identifier>ISSN: 0008-543X</identifier><identifier>EISSN: 1097-0142</identifier><identifier>DOI: 10.1002/1097-0142(197809)42:3+&lt;1484::AID-CNCR2820420819&gt;3.0.CO;2-J</identifier><identifier>PMID: 709519</identifier><language>eng</language><publisher>New York: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Carcinoembryonic Antigen ; Carcinoma, Bronchogenic - blood ; Carcinoma, Bronchogenic - mortality ; Carcinoma, Bronchogenic - surgery ; Humans ; Lung Neoplasms - blood ; Lung Neoplasms - mortality ; Lung Neoplasms - surgery ; Neoplasm Metastasis ; Prognosis ; Reference Values ; Smoking</subject><ispartof>Cancer, 1978-09, Vol.42 (S3), p.1484-1491</ispartof><rights>Copyright © 1978 American Cancer Society</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c4639-34dac14bdb9b45a59b9afabba9bb8cdd9be0d2ab52e01d2226942fab909160e33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/709519$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dent, Peter B.</creatorcontrib><creatorcontrib>McCulloch, Peter B.</creatorcontrib><creatorcontrib>Wesley‐James, Oliver</creatorcontrib><creatorcontrib>Maclaren, Robert</creatorcontrib><creatorcontrib>Muirhead, William</creatorcontrib><creatorcontrib>Dunnett, Charles W.</creatorcontrib><title>Measurement of carcinoembryonic antigen in patients with bronchogenic carcinoma</title><title>Cancer</title><addtitle>Cancer</addtitle><description>Estimation of CEA levels by the Z‐gel method indicates that smokers, patients with limited lung cancer and patients with extensive lung cancer have higher values than nonsmoking controls. The CEA levels within each group are significantly different from one another. Use of CEA estimation for diagnostic purposes is limited because of the considerable overlap between normal controls and patients with cancer, the relatively low incidence of elevated values in patients with limited disease and the high incidence of false negatives (20%) even in patients with extensive disease. Elevated CEA values are associated with a poor prognosis and could be of clinical value as an addition to clinical staging to determine survival particularly for patients with extrathoracic disease. Persistently high values in patients deemed clinically disease‐free postoperatively are indicative of residual disease and a poor prognosis. If and when effective therapy for bronchogenic carcinoma becomes available, monitoring of CEA values may be useful in some patients as an early indication of relapse. Further studies are required to determine if the extraordinarily poor prognosis associated with marked elevations of CEA may be used as an additional criterion of inoperability in such patients.</description><subject>Carcinoembryonic Antigen</subject><subject>Carcinoma, Bronchogenic - blood</subject><subject>Carcinoma, Bronchogenic - mortality</subject><subject>Carcinoma, Bronchogenic - surgery</subject><subject>Humans</subject><subject>Lung Neoplasms - blood</subject><subject>Lung Neoplasms - mortality</subject><subject>Lung Neoplasms - surgery</subject><subject>Neoplasm Metastasis</subject><subject>Prognosis</subject><subject>Reference Values</subject><subject>Smoking</subject><issn>0008-543X</issn><issn>1097-0142</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1978</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkF9LHDEUxYOodWv9Bn2Yp6LIbG_-zM5kK4JO1SrWBVEQXy5JJltTdmbWZBbZb2_WWYT2ofTp5nLOPSf8CDmlMKQA7CsFmadABdunMi9AHgg25odHVBRiPD65_J6WN-UtKxgIBgWVx3wIw3LyjaVXG2TwfrxJBgBQpJngDzvkYwi_45qzjH8g2znIjMoBmfy0Kiy8rW3TJe00Mcob17S21n7ZNs4kquncL9skrknmqnPRFpIX1z0l2reNeWqjFl3rs1p9IltTNQt2bz13yf352V35I72eXFyWJ9epESMuUy4qZajQlZZaZCqTWqqp0lpJrQtTVVJbqJjSGbNAK8bYSAoWDRIkHYHlfJd86XPnvn1e2NBh7YKxs5lqbLsImAtGMw5FND72RuPbELyd4ty7WvklUsAVbFzxwhUv7GFjfHHEFWzECBv_hB01wHKCDK9i-Of1Lxa6ttV7dE83ylUvv7iZXf5n8VvvP2v_UvgrbDueDw</recordid><startdate>197809</startdate><enddate>197809</enddate><creator>Dent, Peter B.</creator><creator>McCulloch, Peter B.</creator><creator>Wesley‐James, Oliver</creator><creator>Maclaren, Robert</creator><creator>Muirhead, William</creator><creator>Dunnett, Charles W.</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>197809</creationdate><title>Measurement of carcinoembryonic antigen in patients with bronchogenic carcinoma</title><author>Dent, Peter B. ; McCulloch, Peter B. ; Wesley‐James, Oliver ; Maclaren, Robert ; Muirhead, William ; Dunnett, Charles W.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4639-34dac14bdb9b45a59b9afabba9bb8cdd9be0d2ab52e01d2226942fab909160e33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1978</creationdate><topic>Carcinoembryonic Antigen</topic><topic>Carcinoma, Bronchogenic - blood</topic><topic>Carcinoma, Bronchogenic - mortality</topic><topic>Carcinoma, Bronchogenic - surgery</topic><topic>Humans</topic><topic>Lung Neoplasms - blood</topic><topic>Lung Neoplasms - mortality</topic><topic>Lung Neoplasms - surgery</topic><topic>Neoplasm Metastasis</topic><topic>Prognosis</topic><topic>Reference Values</topic><topic>Smoking</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dent, Peter B.</creatorcontrib><creatorcontrib>McCulloch, Peter B.</creatorcontrib><creatorcontrib>Wesley‐James, Oliver</creatorcontrib><creatorcontrib>Maclaren, Robert</creatorcontrib><creatorcontrib>Muirhead, William</creatorcontrib><creatorcontrib>Dunnett, Charles W.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dent, Peter B.</au><au>McCulloch, Peter B.</au><au>Wesley‐James, Oliver</au><au>Maclaren, Robert</au><au>Muirhead, William</au><au>Dunnett, Charles W.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Measurement of carcinoembryonic antigen in patients with bronchogenic carcinoma</atitle><jtitle>Cancer</jtitle><addtitle>Cancer</addtitle><date>1978-09</date><risdate>1978</risdate><volume>42</volume><issue>S3</issue><spage>1484</spage><epage>1491</epage><pages>1484-1491</pages><issn>0008-543X</issn><eissn>1097-0142</eissn><abstract>Estimation of CEA levels by the Z‐gel method indicates that smokers, patients with limited lung cancer and patients with extensive lung cancer have higher values than nonsmoking controls. The CEA levels within each group are significantly different from one another. Use of CEA estimation for diagnostic purposes is limited because of the considerable overlap between normal controls and patients with cancer, the relatively low incidence of elevated values in patients with limited disease and the high incidence of false negatives (20%) even in patients with extensive disease. Elevated CEA values are associated with a poor prognosis and could be of clinical value as an addition to clinical staging to determine survival particularly for patients with extrathoracic disease. Persistently high values in patients deemed clinically disease‐free postoperatively are indicative of residual disease and a poor prognosis. If and when effective therapy for bronchogenic carcinoma becomes available, monitoring of CEA values may be useful in some patients as an early indication of relapse. Further studies are required to determine if the extraordinarily poor prognosis associated with marked elevations of CEA may be used as an additional criterion of inoperability in such patients.</abstract><cop>New York</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>709519</pmid><doi>10.1002/1097-0142(197809)42:3+&lt;1484::AID-CNCR2820420819&gt;3.0.CO;2-J</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0008-543X
ispartof Cancer, 1978-09, Vol.42 (S3), p.1484-1491
issn 0008-543X
1097-0142
language eng
recordid cdi_proquest_miscellaneous_74215308
source MEDLINE; Alma/SFX Local Collection
subjects Carcinoembryonic Antigen
Carcinoma, Bronchogenic - blood
Carcinoma, Bronchogenic - mortality
Carcinoma, Bronchogenic - surgery
Humans
Lung Neoplasms - blood
Lung Neoplasms - mortality
Lung Neoplasms - surgery
Neoplasm Metastasis
Prognosis
Reference Values
Smoking
title Measurement of carcinoembryonic antigen in patients with bronchogenic carcinoma
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T23%3A57%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Measurement%20of%20carcinoembryonic%20antigen%20in%20patients%20with%20bronchogenic%20carcinoma&rft.jtitle=Cancer&rft.au=Dent,%20Peter%20B.&rft.date=1978-09&rft.volume=42&rft.issue=S3&rft.spage=1484&rft.epage=1491&rft.pages=1484-1491&rft.issn=0008-543X&rft.eissn=1097-0142&rft_id=info:doi/10.1002/1097-0142(197809)42:3+%3C1484::AID-CNCR2820420819%3E3.0.CO;2-J&rft_dat=%3Cproquest_cross%3E74215308%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=74215308&rft_id=info:pmid/709519&rfr_iscdi=true